Biodexa announces milestone in Serenta Phase 3 FAP trial
Biodexa announces a major milestone for its Serenta registrational Phase 3 trial in FAP, with no further details or catalyst supplied in the alert.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.